Glucocorticoid-prescribing trends in congenital adrenal hyperplasia, 2017 to 2023
Objective: This study investigates the utilisation of modern glucocorticoid medications (Acecort®, Alkindi®, Efmody®, and Plenadren®) for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, examining prescribing patterns, barriers to adoption, and geographical and temporal trends. Metho...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Bioscientifica
2026-03-01
|
| Ráidu: | Endocrine Connections |
| Fáttát: | |
| Liŋkkat: | https://ec.bioscientifica.com/view/journals/ec/15/3/EC-25-0565.xml |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
